A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Mainz Biomed N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 18,157 shares of MYNZ stock, worth $10,894. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,157
Previous 33,244 45.38%
Holding current value
$10,894
Previous $38,000 52.63%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.88 - $1.2 $13,276 - $18,104
-15,087 Reduced 45.38%
18,157 $18,000
Q4 2023

Feb 14, 2024

BUY
$1.04 - $3.15 $34,573 - $104,718
33,244 New
33,244 $38,000

Others Institutions Holding MYNZ

About MAINZ BIOMED N.V.


  • Ticker MYNZ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 14,483,000
  • Market Cap $8.69M
  • Description
  • Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments...
More about MYNZ
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.